Director sold ~$132K of Teradyne
Scheduled in advanceTraded Dec 5, 2025 · Filed Dec 9, 2025
A board member of Teradyne sold $125K of Teradyne shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$125,000
Shares × reported transaction price
37 days after results of Oct 29, 2025, 60 days before results of Feb 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $200.77 on Dec 5, 2025, at its 52-week high, after a 38% rise over the previous 30 trading days
52-week range $67.96 (Apr 8, 2025) to $200.77 (Dec 5, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $145.04 on Oct 23, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -3.8% | -0.6% | -3.2% |
| 30 days | +8.2% | +0.9% | +7.2% |
| 90 days | +48.2% | -0.7% | +48.9% |
| 180 days | +87.4% | +8.2% | +79.2% |
Past results only. Not a forecast.
Director sold ~$132K of Teradyne
Scheduled in advanceCompensation award — excluded from discretionary-purchase analysis.
Not classified as an open-market trade.